NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus MSCs in Patients with Osteoarthritis

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the Australian National Health...

Cynata’s Cymerus MSCs Ameliorate Cytokine Release Syndrome in Preclinical Study

Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX:CYP) is pleased to announce data from a preclinical model demonstrating...

Cynata Reports Positive Six-Month Data from Cohort A in Phase 1 Trial of CYP-001 in GvHD

Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and sustained overall...